**Example of print screens of the values clarification method (VCM) for a male patient. Section 1.**

0% ▬▬▬ 100%

The probability of recurrence of the tumour at the site:

2 of 100 people **will have** a recurrence (**98** of 100 people **will not**)	**or**	**10** of 100 people **will have** a recurrence (**90** of 100 people **will not**)

How **important** do you consider this difference in probability of recurrence?

○ Not at all important

○ Somewhat important

○ Important

○ Very important

<<	Next page

Section 2.

Which of these two situations would you prefer and how strong is this preference?

Recurrence of the tumour at the site
of the 100 people:

10 will	90 will not

Faecal incontinence
of the 100 people:

50 will	50 will not

Sexual dysfunction
of the 100 men:

50 will	50 will not

or

Recurrence of the tumour at the site
of the 100 people:

6 will	94 will not

Faecal incontinence
of the 100 people:

65 will	35 will not

Sexual dysfunction
of the 100 men:

70 will	30 will not

○　　　○　　　○　　　○　　　○　　　○　　　○

Strong
preference   -------------   -------------   No   -------------   -------------   Strong
for left   preference   preference
                                                                                              for right

<<	Next page

Section 3.

ABEL - STUDY

This overview shows how <u>important</u> you consider the treatment outcomes, according to <u>this questionnaire</u>.
The more points a treatment outcome has, <u>the more important you seem to consider this outcome</u>.

Based on your answers, the 100 points are divided as follows:

The number of points for **recurrence of the tumour at the site**

<div style="background-color:orange">35</div>

The number of points for **fecal incontinence**

<div style="background-color:orange">39</div>

The number of points for **sexual dysfunction**

<div style="background-color:orange">27</div>

Click <u>here</u> to print this overview

Note.
ABEL was the study acronym, which stands for 'Trade-offs in radiotherapy treatment for rectal cancer'.